Sutro Biopharma News (STRO) - Investing.com

Investing.com - Sutro Biopharma (NASDAQ: STRO) reported third quarter EPS of $-0.590, $0.14 better than the analyst estimate of $-0.730. Revenue for the quarter came in at $8.5M... By …

$0.14
OFF

Sutro Biopharma News (STRO) - Investing.com

2 weeks from now

Investing.com - Sutro Biopharma (NASDAQ: STRO) reported third quarter EPS of $-0.590, $0.14 better than the analyst estimate of $-0.730. Revenue for the quarter came in at $8.5M... By …

investing.com

$12.00
OFF

Sutro Biopharma Retains Stock Target With Buy Rating On Key ...

2 weeks from now

Oct 11, 2024 · On Friday, H.C. Wainwright reaffirmed its positive stance on Sutro Biopharma (NASDAQ: STRO) shares, maintaining a Buy rating with a $12.00 price target. The …

investing.com

$1
OFF

Sutro Biopharma Stock Hits 52-week Low At $1.7 Amid Market …

2 weeks from now

2 days ago · Sutro Biopharma Inc. (NASDAQ: STRO) stock has tumbled to a 52-week low, touching down at $1.7 USD, as the biopharmaceutical company faces a challenging market …

investing.com

$1
OFF

Sutro Biopharma Stock Hits 52-week Low At $1.7 Amid Market …

2 weeks from now

2 days ago · Sutro Biopharma Inc. (NASDAQ: STRO) stock has tumbled to a 52-week low, touching down at $1.7 USD, as the biopharmaceutical company faces a challenging market …

investing.com

$2.02
OFF

Sutro Biopharma Stock Hits 52-week Low At $2.02 - Ng.investing.com

2 weeks from now

Dec 18, 2024 · The 52-week low serves as a critical juncture for Sutro Biopharma (NASDAQ: STRO), as market participants consider the company's future prospects and potential for …

investing.com

$11
OFF

Sutro Biopharma News (STRO) - Investing.com

2 weeks from now

On Wednesday, Sutro Biopharma (NASDAQ:STRO)'s share price target was lowered to $11 from $12 by Piper Sandler, while the firm maintained an Overweight rating on the company. The...

investing.com

$17.00
OFF

Strong Buy Rating For Sutro Biopharma Amid Promising Trial …

2 weeks from now

Dec 11, 2024 · Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), retaining the price target of $17.00. Pick the best …

businessinsider.com

$1
OFF

Sutro Biopharma Stock Hits 52-week Low At $1.7 Amid Market …

2 weeks from now

2 days ago · Sutro Biopharma Inc. (NASDAQ: STRO) stock has tumbled to a 52-week low, touching down at $1.7 USD, as the biopharmaceutical company faces a challenging market …

investing.com

$5.00
OFF

Sutro Biopharma Inc (STRO) Stock Message Board - InvestorsHub

2 weeks from now

Jan 1, 2025 · STRO: I launched this new iHub board today due to the below-pasted reply I got from GOOGLE's (AI) search routine regarding my following question: "Which (under $5.00) …

advfn.com

$0.14
OFF

Sutro Biopharma Stock Price Today | NASDAQ: STRO Live

2 weeks from now

Investing.com - Sutro Biopharma (NASDAQ: STRO) reported third quarter EPS of $-0.590, $0.14 better than the analyst estimate of $-0.730. Revenue for the quarter came in at $8.5M...

investing.com

$2.02
OFF

Sutro Biopharma Stock Hits 52-week Low At $2.02 - Investing.com

2 weeks from now

Dec 18, 2024 · The 52-week low serves as a critical juncture for Sutro Biopharma (NASDAQ: STRO), as market participants consider the company's future prospects and potential for …

investing.com

FAQs about Sutro Biopharma News (STRO) - Investing.com Coupon?

Should you buy Sutro Biopharma (Stro) stock?

Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), retaining the price target of $17.00. Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! ...

Who owns Sutro Biopharma stock?

In the past three months, Sutro Biopharma insiders have not sold or bought any company stock. Only 5.90% of the stock of Sutro Biopharma is held by insiders. 96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. ...

How did Sutro Biopharma (Stro) perform in the quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) posted its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.20. The firm had revenue of $25.71 million for the quarter, compared to analyst estimates of $26.28 million. ...

Is Sutro Biopharma a good buy?

Sutro Biopharma scored higher than 93% of companies evaluated by MarketBeat, and ranked 78th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Sutro Biopharma has received a consensus rating of Moderate Buy. ...

Who is Sutro Biopharma?

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. ...

What is Sutro Biopharma's news sentiment?

Sutro Biopharma has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies. ...